JXL069

JXL069 is an experimental drug originally developed at the University of California, Los Angeles (UCLA) and licensed for development to Pelage Pharmaceuticals, which acts as a potent and selective mitochondrial pyruvate carrier (MPC) inhibitor that disrupts pyruvate import into mitochondria. It has been researched as a potential treatment for androgenetic alopecia and shows positive results in animal studies. Pelage Pharmaceuticals currently has a related candidate molecule PP405 in phase 2 clinical trials for hair loss formulated as a topical cream for the scalp.^[1][2] MPC inhibitors also have potential for the treatment of cancer, so a large number of related molecules have also been developed, of which JXL069 was among the most effective tested so far for treatment of hair loss.^{[3][4][5][6][7][8]} The drug is known to have been sold online in a grey market fashion for treatment of hair loss.^[9] It has been believed to be PP405, but PP405 was said not to be JXL069 by Pelage Pharmaceuticals.^[9]

JXL069

Clinical data
Drug class	Mitochondrial pyruvate carrier (MPC) inhibitor
Identifiers
IUPAC name 3-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]pyrrolo[2,3-b]pyridin-3-yl]-2-cyanoprop-2-enoic acid
CAS Number	2260696-63-5
PubChem CID	175007307
ChemSpider	123961728
Chemical and physical data
Formula	C20H11F6N3O2
Molar mass	439.317 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1=CC2=C(N=C1)N(C=C2C=C(C#N)C(=O)O)CC3=CC(=CC(=C3)C(F)(F)F)C(F)(F)F
InChI InChI=1S/C20H11F6N3O2/c21-19(22,23)14-4-11(5-15(7-14)20(24,25)26)9-29-10-13(6-12(8-27)18(30)31)16-2-1-3-28-17(16)29/h1-7,10H,9H2,(H,30,31) Key:IGVIZFSCSSEYDA-UHFFFAOYSA-N

See also

• List of investigational hair loss drugs
• PP405
• JXL082